Myc proteins as therapeutic targets.

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer (2013) 2.17

Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell (2012) 1.81

Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75

An overview of MYC and its interactome. Cold Spring Harb Perspect Med (2014) 1.53

The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. J Natl Cancer Inst (2015) 1.46

Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell (2014) 1.33

Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell (2012) 1.24

The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ (2012) 1.16

CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer (2010) 1.16

Molecular networks of human muscle adaptation to exercise and age. PLoS Genet (2013) 1.14

The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One (2011) 1.10

Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget (2010) 1.07

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front Oncol (2012) 1.04

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer (2014) 1.01

The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms. Clin Exp Metastasis (2013) 0.97

Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol (2012) 0.96

Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer (2010) 0.94

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol (2013) 0.94

CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene (2013) 0.93

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas. PLoS Genet (2014) 0.93

The enforced expression of c-Myc in pig fibroblasts triggers mesenchymal-epithelial transition (MET) via F-actin reorganization and RhoA/Rock pathway inactivation. Cell Cycle (2013) 0.91

mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis (2015) 0.90

New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol (2012) 0.89

IκB kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol Cancer (2011) 0.88

The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci U S A (2013) 0.88

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS One (2013) 0.88

Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg (2013) 0.87

Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis. Cancer Biol Ther (2011) 0.87

MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma. Leukemia (2013) 0.87

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proc Natl Acad Sci U S A (2016) 0.86

Induced pluripotent cancer cells: progress and application. J Cancer Res Clin Oncol (2010) 0.85

Neuroblastoma in a 55-year-old patient: a case report. Case Rep Oncol (2010) 0.85

Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice. Leukemia (2011) 0.85

Microflora in colorectal cancer: a friend to fear. Nat Med (2010) 0.84

Characterization of common marmoset dysgerminoma-like tumor induced by the lentiviral expression of reprogramming factors. Cancer Sci (2014) 0.84

Upregulation of LYAR induces neuroblastoma cell proliferation and survival. Cell Death Differ (2017) 0.84

MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. J Cancer Res Clin Oncol (2014) 0.83

Akt2 regulates metastatic potential in neuroblastoma. PLoS One (2013) 0.82

An unexpected role for caspase-2 in neuroblastoma. Cell Death Dis (2014) 0.81

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression. Oncogenesis (2012) 0.81

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget (2015) 0.81

Myc proteins in brain tumor development and maintenance. Ups J Med Sci (2012) 0.80

New model systems provide insights into Myc-induced transformation. Oncogene (2011) 0.80

Multiple roles of toll-like receptor 4 in colorectal cancer. Front Immunol (2014) 0.80

MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system . Neuro Oncol (2014) 0.80

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Front Oncol (2015) 0.79

GSTT1 deletion is related to polycyclic aromatic hydrocarbons-induced DNA damage and lymphoma progression. PLoS One (2014) 0.79

Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol (2015) 0.78

Constitutive gray hair in mice induced by melanocyte-specific deletion of c-Myc. Pigment Cell Melanoma Res (2012) 0.78

The ciliary protein cystin forms a regulatory complex with necdin to modulate Myc expression. PLoS One (2013) 0.77

Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr (2016) 0.77

Regulation of Differentiation by Calcium-Sensing Receptor in Normal and Tumoral Developing Nervous System. Front Physiol (2016) 0.76

The complexity of epigenetic diseases. J Pathol (2015) 0.76

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget (2016) 0.76

Addiction to B-MYB. Oncotarget (2010) 0.75

High phosphohistone H3 expression correlates with adverse clinical, biological, and pathological factors in neuroblastomas. J Histochem Cytochem (2015) 0.75

High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas. Virchows Arch (2015) 0.75

FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery (2016) 0.75

The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget (2016) 0.75

Altered transcription and replication are the mechanisms of cytotoxicity of antitumor antibiotic olivomycin A. Dokl Biochem Biophys (2010) 0.75

Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31

Induction of apoptosis in fibroblasts by c-myc protein. Cell (1992) 16.95

Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89

Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73

Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46

Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science (1991) 12.00

Genomic targets of the human c-Myc protein. Genes Dev (2003) 9.67

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63

Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature (1982) 9.12

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03

The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol (2000) 8.47

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79

Sequence-specific DNA binding by the c-Myc protein. Science (1990) 7.75

Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44

Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38

A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30

Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54

Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell (1993) 6.40

Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev (2001) 6.36

Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80

Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78

Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell (1991) 5.76

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74

Insights from genomic profiling of transcription factors. Nat Rev Genet (2009) 5.57

Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev (2001) 5.37

The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37

Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene (1991) 5.32

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32

Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell (1993) 5.28

Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27

The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07

Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95

Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92

N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J (2001) 4.85

Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol (2006) 4.71

Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55

Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35

Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22

Myc and Max proteins possess distinct transcriptional activities. Nature (1992) 4.16

Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16

Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol (1993) 4.08

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell (2009) 3.92

Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development (2003) 3.88

The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol (2000) 3.86

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80

N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev (2002) 3.71

TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69

Differential expression of myc family genes during murine development. Nature (1986) 3.57

Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature (1985) 3.50

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A (1999) 3.49

Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature (1992) 3.43

Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene (2008) 3.31

Myc and Max associate in vivo. Genes Dev (1992) 3.16

Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev (2001) 3.15

Twist is a potential oncogene that inhibits apoptosis. Genes Dev (1999) 3.14

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07

Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res (2009) 3.03

c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol (2000) 2.96

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature (2008) 2.95

Aurora kinases as anticancer drug targets. Clin Cancer Res (2008) 2.92

Ras enhances Myc protein stability. Mol Cell (1999) 2.91

Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science (1992) 2.90

Max: functional domains and interaction with c-Myc. Genes Dev (1992) 2.88

Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer (2004) 2.83

Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell (2009) 2.79

Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A (2003) 2.72

Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. Development (2005) 2.64

Apoptotic signaling by c-MYC. Oncogene (2008) 2.57

Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene (2003) 2.57

Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet (1993) 2.47

Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47

Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development (2003) 2.42

Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev (1997) 2.37

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36

p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature (2004) 2.26

N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts. Mol Cell Biol (1990) 2.24

Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am (2008) 2.24

Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep (2003) 2.21

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A (2005) 2.19

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev (2008) 2.17

Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One (2008) 2.12

Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09

c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 2.08

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene (2007) 2.07

Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene (1994) 2.05

MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol (2000) 2.02

Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol (1994) 2.01

Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol (2006) 2.00

Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. Genes Dev (1992) 1.97

Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev (1997) 1.96

Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell (2005) 1.94

Normal yeast tRNA(CAGGln) can suppress amber codons and is encoded by an essential gene. J Mol Biol (1986) 1.69

Molecular cloning and characterization of the yeast RAD10 gene and expression of RAD10 protein in E. coli. EMBO J (1985) 1.36

Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. Oncogene (2009) 1.18

Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol (2000) 1.10

Characterization of the RAD10 gene of Saccharomyces cerevisiae and purification of Rad10 protein. Biochemistry (1990) 0.96

A yeast DNA repair gene partially complements defective excision repair in mammalian cells. EMBO J (1988) 0.88

Nucleotide excision repair genes from the yeast Saccharomyces cerevisiae. Basic Life Sci (1986) 0.81

Divergent genetic codes. Nature (1987) 0.80

Molecular approaches to the study of nucleotide excision repair in eukaryotes. Basic Life Sci (1986) 0.77

Lung cancer type in relation to cigarette dosage. Cancer (1977) 0.75

The use and abuse of muscle relaxants. J Am Assoc Nurse Anesth (1970) 0.75

Toxicity of cigarette-smoke solutions for Paramecium. Influence of variations in smoking technique. Arch Environ Health (1966) 0.75

The gas phase toxicity of cigarette smoke for Paramecium. Arch Environ Health (1967) 0.75